Tvardi Therapeutics (TVRD) Invested Capital: 2013-2017
Historic Invested Capital for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $99.1 million.
- Tvardi Therapeutics' Invested Capital rose 37.98% to $99.1 million in Q3 2017 from the same period last year, while for Sep 2017 it was $99.1 million, marking a year-over-year increase of 37.98%. This contributed to the annual value of $50.7 million for FY2016, which is 51.71% down from last year.
- Per Tvardi Therapeutics' latest filing, its Invested Capital stood at $99.1 million for Q3 2017, which was down 9.29% from $109.2 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' Invested Capital ranged from a high of $113.9 million in Q3 2015 and a low of -$55.3 million during Q1 2013.
- Over the past 3 years, Tvardi Therapeutics' median Invested Capital value was $82.6 million (recorded in 2016), while the average stood at $76.9 million.
- Per our database at Business Quant, Tvardi Therapeutics' Invested Capital skyrocketed by 227.13% in 2014 and then crashed by 69.17% in 2017.
- Tvardi Therapeutics' Invested Capital (Quarterly) stood at -$54.1 million in 2013, then skyrocketed by 195.54% to $51.7 million in 2014, then spiked by 103.33% to $105.0 million in 2015, then plummeted by 51.71% to $50.7 million in 2016, then spiked by 37.98% to $99.1 million in 2017.
- Its Invested Capital was $99.1 million in Q3 2017, compared to $109.2 million in Q2 2017 and $29.3 million in Q1 2017.